Muon Collider Physics Summary

The perspective of designing muon colliders with high energy and luminosity,which is being investigated by the International Muon Collider Collaboration,has triggered a growing interest in their physics reach. We present a concisesummary of the muon colliders potential to explore new physics, leveraging onthe unique possibility of combining high available energy with very precisemeasurements.<br

Muon Collider Physics Summary

The perspective of designing muon colliders with high energy and luminosity,which is being investigated by the International Muon Collider Collaboration,has triggered a growing interest in their physics reach. We present a concisesummary of the muon colliders potential to explore new physics, leveraging onthe unique possibility of combining high available energy with very precisemeasurements.<br

The physics case of a 3 TeV muon collider stage

In the path towards a muon collider with center of mass energy of 10 TeV ormore, a stage at 3 TeV emerges as an appealing option. Reviewing the physicspotential of such muon collider is the main purpose of this document. In orderto outline the progression of the physics performances across the stages, a fewsensitivity projections for higher energy are also presented. There are manyopportunities for probing new physics at a 3 TeV muon collider. Some of themare in common with the extensively documented physics case of the CLIC 3 TeVenergy stage, and include measuring the Higgs trilinear coupling and testingthe possible composite nature of the Higgs boson and of the top quark at the 20TeV scale. Other opportunities are unique of a 3 TeV muon collider, and stemfrom the fact that muons are collided rather than electrons. This isexemplified by studying the potential to explore the microscopic origin of thecurrent $g$-2 and $B$-physics anomalies, which are both related with muons.<br

The physics case of a 3 TeV muon collider stage

In the path towards a muon collider with center of mass energy of 10 TeV ormore, a stage at 3 TeV emerges as an appealing option. Reviewing the physicspotential of such muon collider is the main purpose of this document. In orderto outline the progression of the physics performances across the stages, a fewsensitivity projections for higher energy are also presented. There are manyopportunities for probing new physics at a 3 TeV muon collider. Some of themare in common with the extensively documented physics case of the CLIC 3 TeVenergy stage, and include measuring the Higgs trilinear coupling and testingthe possible composite nature of the Higgs boson and of the top quark at the 20TeV scale. Other opportunities are unique of a 3 TeV muon collider, and stemfrom the fact that muons are collided rather than electrons. This isexemplified by studying the potential to explore the microscopic origin of thecurrent $g$-2 and $B$-physics anomalies, which are both related with muons.<br

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Towards a Muon Collider

A muon collider would enable the big jump ahead in energy reach that is needed for a fruitful exploration of fundamental interactions. The challenges of producing muon collisions at high luminosity and 10 TeV centre of mass energy are being investigated by the recently-formed International Muon Collider Collaboration. This Review summarises the status and the recent advances on muon colliders design, physics and detector studies. The aim is to provide a global perspective of the field and to outline directions for future work.Comment: 118 pages, 103 figure

Towards a muon collider

A muon collider would enable the big jump ahead in energy reach that is needed for a fruitful exploration of fundamental interactions. The challenges of producing muon collisions at high luminosity and 10 TeV centre of mass energy are being investigated by the recently-formed International Muon Collider Collaboration. This Review summarises the status and the recent advances on muon colliders design, physics and detector studies. The aim is to provide a global perspective of the field and to outline directions for future work